GlaxoSmithKline also registered Retrovir 300 mg x 60, Retrovir 250 mg x 40 and Trizivir 750 mg x 60 under the Regulation in 2004, but there were no sales under tiered prices of these products in the reporting period.
GlaxoSmithKline 2004. gadā saskaņā ar šo regulu reģistrēja arī Retrovir 300 mg x 60, Retrovir 250 mg x 40 un Trizivir 750 mg x 60, taču pārskata periodā netika veikta šo produktu pārdošana par diferencētām cenām.